Skip to main content
Top
Published in: Rheumatology International 7/2019

01-07-2019 | Systemic Lupus Erythematosus | Observational Research

Indications for bone marrow examinations in rheumatology

Authors: Hava Üsküdar Teke, Döndü Üsküdar Cansu, Cengiz Korkmaz

Published in: Rheumatology International | Issue 7/2019

Login to get access

Abstract

Hematologic involvement or hematologic malignancies are frequently encountered during the course of rheumatic diseases. Bone marrow (BM) aspiration and/or biopsy examinations may have a diagnostic role in explaining hematologic findings detected in rheumatology clinical practice. Our aim was to describe the indications for BM examinations and to share our BM aspiration/biopsy results. We analyzed 140 BM aspiration/biopsy results of patients conducted at the Department of Rheumatology from 2010 to 2018. Demographics, complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) values, serum biochemistry test results including lactate dehydrogenase (LDH), organomegaly, indications for BM examinations and BM examination results for each patient, and mortality rates were recorded. Out of the 140 patients, 63.6% were female, and the median (Q1–Q3) age was 53 (39.5–65) years. One hundred fifteen (82.1%) patients were diagnosed as having primary rheumatic disease, and 25 (17.8%) were admitted due to musculoskeletal symptoms. Rheumatoid arthritis (RA) (n = 34, [29.5%]), and systemic lupus erythematosus (SLE) (n = 21, [18.2%]) were the most common rheumatic diseases. Cytopenia was the most common indication for BM aspiration/biopsy (n = 83, [59.3%]). Thirty-nine (47%) of 83 patients had drug-induced cytopenia. A pathology was detected in 40 (28.5%) of the 140 BM examinations. Patients with pathologic BM results had either a hematologic malignancy (n = 38, [95%]) or metastasis to a solid organ (n = 2, [5%]). The group of patients with pathologic BM biopsy results had significantly higher rates of lymphadenopathy, splenomegaly, and monoclonal gammopathy compared with the group with non-pathologic results (p = 0.001, p = 0.011, and p = 0.023, respectively). Likewise, LDH concentrations of those with pathologic results were higher than in patients with non-pathologic results [737 (range 577–1420) IU/L vs. 541 (range 306–840) IU/L, p = 0.019]. In this study, cytopenia or CBC abnormalities accompanied by elevated LDH values or anemia along with increased ESR were the most common indications for BM aspiration/biopsy. Further prospective studies are needed to determine the indications of BM aspiration/biopsy and establish the parameters that predict abnormal BM results in rheumatology practice.
Literature
1.
go back to reference Lee SH, Erber WN, Porwit A, Tomonaga M, Peterson LC (2008) ICSH guidelines for the standardizations of bone marrow specimens and reports. Int Jnl Lab Hem 30:349–364CrossRef Lee SH, Erber WN, Porwit A, Tomonaga M, Peterson LC (2008) ICSH guidelines for the standardizations of bone marrow specimens and reports. Int Jnl Lab Hem 30:349–364CrossRef
3.
go back to reference Bain BJ (2006) Morbidity associated with bone marrow aspiration and trephine biopsy: a review of UK data for 2004. Haematologica 91:1293–1294PubMed Bain BJ (2006) Morbidity associated with bone marrow aspiration and trephine biopsy: a review of UK data for 2004. Haematologica 91:1293–1294PubMed
4.
go back to reference Garton MJ, Keir G, Dickie A, Steven M, Rennie JA (2006) Prevalence and long-term significance of paraproteinaemia in rheumatoid arthritis. Rheumatology 45:355–356CrossRefPubMed Garton MJ, Keir G, Dickie A, Steven M, Rennie JA (2006) Prevalence and long-term significance of paraproteinaemia in rheumatoid arthritis. Rheumatology 45:355–356CrossRefPubMed
5.
go back to reference Loctin A, Bailly F, Laroche D, Tavernier C, Maillefert JF, Ornetti P (2013) Clinical interest of bone marrow aspiration in rheumatology: a practice-based observational study of 257 bone marrow aspirations. Clin Rheumatol 32:115–121CrossRefPubMed Loctin A, Bailly F, Laroche D, Tavernier C, Maillefert JF, Ornetti P (2013) Clinical interest of bone marrow aspiration in rheumatology: a practice-based observational study of 257 bone marrow aspirations. Clin Rheumatol 32:115–121CrossRefPubMed
6.
go back to reference Richter JG, Gossen P, Germing U, Blum S, Hildebrandt B, Braunstein S, Huscher D, Schneider M (2009) Rationale for bone marrow examination in patients with inflammatory rheumatic diseases. Wen Klin Wochenschr 121:690–699CrossRef Richter JG, Gossen P, Germing U, Blum S, Hildebrandt B, Braunstein S, Huscher D, Schneider M (2009) Rationale for bone marrow examination in patients with inflammatory rheumatic diseases. Wen Klin Wochenschr 121:690–699CrossRef
7.
go back to reference Hunt KE, Salama ME, Sever CE, Foucar K (2013) Bone marrow examination for unexplained cytopenias reveals nonspesific findings patients with collagen vascular disease. Arch Pathol Lab Med 137:948–954CrossRefPubMed Hunt KE, Salama ME, Sever CE, Foucar K (2013) Bone marrow examination for unexplained cytopenias reveals nonspesific findings patients with collagen vascular disease. Arch Pathol Lab Med 137:948–954CrossRefPubMed
8.
go back to reference Üsküdar Cansu D, Üsküdar Teke H, Işiksoy S, Korkmaz C (2018) Bone marrow as a target organ of systemic lupus erythematosus: analysis of cases with myelofibrosis. Int J Rheum Dis 21:1049–1059CrossRefPubMed Üsküdar Cansu D, Üsküdar Teke H, Işiksoy S, Korkmaz C (2018) Bone marrow as a target organ of systemic lupus erythematosus: analysis of cases with myelofibrosis. Int J Rheum Dis 21:1049–1059CrossRefPubMed
9.
go back to reference Papageorgiou A, Ziakas PD, Tzioufas AG, Voulgarelis M (2013) Indications for bone marrow examination in autoimmune disorders with concurrent haematologic alterations. Clin Exp Rheumatol 31:76–83PubMed Papageorgiou A, Ziakas PD, Tzioufas AG, Voulgarelis M (2013) Indications for bone marrow examination in autoimmune disorders with concurrent haematologic alterations. Clin Exp Rheumatol 31:76–83PubMed
11.
go back to reference Esatoglu SN, Hatemi G, Salihoglu A, Hatemi I, Soysal T, Celik AF (2015) A reappraisal of the association between Behçet’s disease, myelodysplastic syndrome and the presence of trisomy 8: a systematic literature review. Clin Exp Rheumatol 33(6 Suppl 94):S145–S151PubMed Esatoglu SN, Hatemi G, Salihoglu A, Hatemi I, Soysal T, Celik AF (2015) A reappraisal of the association between Behçet’s disease, myelodysplastic syndrome and the presence of trisomy 8: a systematic literature review. Clin Exp Rheumatol 33(6 Suppl 94):S145–S151PubMed
12.
go back to reference Bornstein G, Furie N, Perel N, Ben-Zvi I, Grossman C (2018) Hematological malignancies mimicking rheumatic syndromes: case series and review of the literature. Rheumatol Int 38:1743–1749CrossRefPubMed Bornstein G, Furie N, Perel N, Ben-Zvi I, Grossman C (2018) Hematological malignancies mimicking rheumatic syndromes: case series and review of the literature. Rheumatol Int 38:1743–1749CrossRefPubMed
13.
go back to reference Kim HA, Kwon JE, Yim H, Suh CH, Jung JY, Han JH (2015) The pathologic findings of skin, lymph node, liver, and bone marrow in patients with adult-onset still disease: a comprehensive analysis of 40 cases. Medicine (Baltimore) 94:e787CrossRef Kim HA, Kwon JE, Yim H, Suh CH, Jung JY, Han JH (2015) The pathologic findings of skin, lymph node, liver, and bone marrow in patients with adult-onset still disease: a comprehensive analysis of 40 cases. Medicine (Baltimore) 94:e787CrossRef
14.
go back to reference Rosenthal NS, Farhi DC (1989) Bone marrow findings in connective tissue disease. Am J Clin Pathol 92:650–654CrossRefPubMed Rosenthal NS, Farhi DC (1989) Bone marrow findings in connective tissue disease. Am J Clin Pathol 92:650–654CrossRefPubMed
15.
go back to reference Curtis BR (2017) Non-chemotherapy drug-induced neutropenia: key points to manage the challenges. Hematology Am Soc Hematol Educ Program. 2017:187–193CrossRefPubMedPubMedCentral Curtis BR (2017) Non-chemotherapy drug-induced neutropenia: key points to manage the challenges. Hematology Am Soc Hematol Educ Program. 2017:187–193CrossRefPubMedPubMedCentral
Metadata
Title
Indications for bone marrow examinations in rheumatology
Authors
Hava Üsküdar Teke
Döndü Üsküdar Cansu
Cengiz Korkmaz
Publication date
01-07-2019
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 7/2019
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-019-04312-w

Other articles of this Issue 7/2019

Rheumatology International 7/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.